MEI Pharma (MEI Pharma) 5-Year Dividend Growth Rate : 0.00% (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is MEI Pharma 5-Year Dividend Growth Rate?

MEI Pharma's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

MEI Pharma's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00. As of today, MEI Pharma's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of MEI Pharma's 5-Year Dividend Growth Rate

For the Biotechnology subindustry, MEI Pharma's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MEI Pharma's 5-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MEI Pharma's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where MEI Pharma's 5-Year Dividend Growth Rate falls into.

MEI Pharma 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

MEI Pharma (NAS:MEIP) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

MEI Pharma's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-1.66
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MEI Pharma 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of MEI Pharma's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

MEI Pharma (MEI Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MEI Pharma Inc (NAS:MEIP) » Definitions » 5-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

0JW9:UK

Address

11455 El Camino Real, Suite 250, San Diego, CA, USA, 92130

Website

https://www.meipharma.com

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Executives

Taheer Datoo	director	181 BAY STREET, SUITE 4200, TORONTO A6 M5J 2T3
James P Flynn	director	41 HARRIS CT, DANVILLE CA 94526
Sujay Kango	director	1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Richard G Ghalie	officer: Chief Medical Officer	C/O FAVRILLE, INC, 10445 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Bruce Ross Winson	10 percent owner	5950 BERKSHIRE LANE, SUITE 510, DALLAS TX 75225
Anson Funds Management Lp	10 percent owner	16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248
Anson Management Gp Llc	10 percent owner	16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248
Anson Advisors Inc.	10 percent owner	155 UNIVERSITY AVENUE, SUITE 207, TORONTO A6 M5H 3B7
Funicular Funds, Lp	10 percent owner	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Amin Nathoo	10 percent owner	155 UNIVERSITY AVENUE, SUITE 207, TORONTO Z4 M5H 3B7
Moez Kassam	10 percent owner	111 PETER STREET, SUITE 904, TORONTO A6 M5V2H1
Justin J. File	officer: CFO and Corporate Secretary	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Jacob Ma-weaver	10 percent owner	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Cable Car Capital Llc	10 percent owner	2261 MARKET STREET #4307, SAN FRANCISCO CA 94114
Baltic Charles V. Iii	director	C/O MARSHALL EDWARDS, INC., 11975 EL CAMINO REAL, SUITE 101, SAN DIEGO CA 92130